The estimated Net Worth of Angela Walsh is at least $254 Tisíc dollars as of 23 May 2022. Ms Walsh owns over 2,000 units of Virios Therapeutics stock worth over $561 and over the last 4 years she sold VIRI stock worth over $0. In addition, she makes $253,451 as CFO, SVP of Fin. a Corp. Sec. & Treasurer at Virios Therapeutics.
Ms has made over 2 trades of the Virios Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently she bought 2,000 units of VIRI stock worth $9,160 on 23 May 2022.
The largest trade she's ever made was buying 2,000 units of Virios Therapeutics stock on 23 May 2022 worth over $9,160. On average, Ms trades about 429 units every 69 days since 2021. As of 23 May 2022 she still owns at least 3,000 units of Virios Therapeutics stock.
You can see the complete history of Ms Walsh stock trades at the bottom of the page.
Angela Walsh is the CFO, SVP of Fin., Corp. Sec. & Treasurer at Virios Therapeutics.
As the CFO, SVP of Fin. a Corp. Sec. & Treasurer of Virios Therapeutics, the total compensation of Ms Walsh at Virios Therapeutics is $253,451. There are 1 executives at Virios Therapeutics getting paid more, with Greg Duncan having the highest compensation of $779,318.
Ms Walsh is 54, she's been the CFO, SVP of Fin. a Corp. Sec. & Treasurer of Virios Therapeutics since . There are 2 older and 1 younger executives at Virios Therapeutics. The oldest executive at Virios Therapeutics, LLC is Dr. R. Michael Gendreau, 65, who is the Chief Medical Officer.
Angela's mailing address filed with the SEC is C/O VIRIOS THERAPEUTICS, INC., 44 MILTON AVENUE, ALPHARETTA, GA, 30009.
Over the last 4 years, insiders at Virios Therapeutics have traded over $468 worth of Virios Therapeutics stock and bought 122,044 units worth $512,255 . The most active insiders traders include John C Thomas, Richard James Whitley a Gregory Scott Duncan. On average, Virios Therapeutics executives and independent directors trade stock every 36 days with the average trade being worth of $874. The most recent stock trade was executed by William Pridgen on 21 August 2023, trading 15,335 units of VIRI stock currently worth $19,936.
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. Its lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was incorporated in 2012 and is headquartered in Alpharetta, Georgia.
Virios Therapeutics executives and other stock owners filed with the SEC include: